ART26.12 Shows Naproxen-Level Pain Relief with Better GI Safety in Osteoarthritis Study
ARTL sits 17% above its 52-week low of $0.961 on light trading volume (0.2× avg).
Summary
Artelo's lead FABP5 inhibitor ART26.12 demonstrated pain relief comparable to naproxen in a nonclinical osteoarthritis model, with significantly less gastric tissue damage. This expands the drug's potential beyond neuropathic pain into the large OA market. The company also announced plans for a multiple ascending dose study in healthy volunteers, with enrollment expected in Q4 2026. The data adds to a growing body of positive nonclinical and Phase 1 results for ART26.12, supporting its differentiation as a non-opioid analgesic.
At the time of this announcement, ARTL was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $0.96 to $60.12. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.